Followers | 520 |
Posts | 40228 |
Boards Moderated | 21 |
Alias Born | 09/16/2007 |
Tuesday, October 21, 2008 2:19:13 PM
Platform Overview
One platform, multiple technologies.
With the Xeo, you can use any and every treatment device Cutera has to offer. You can be sure your investment is secure as the Xeo is an upgradeable platform.
Learn More About Xeo
Flexible and affordable Intelligent Pulsed Light.
The Solera Titan offers the award-winning and popular Titan Procedure. With two different treatment devices - Titan V, and Titan XL - you can deliver the in-demand Titan Procedure to your patients in a way that is tailored to their needs.
Learn More About Solera Titan
The Solera Opus puts some of the most powerful and versatile Intelligent Pulsed Light devices (for skin rejuvenation, hair removal and discrete vascular therapy) available today into your practice, and with Cutera's Future Technology Policy you can be sure that any new IPL device from Cutera is just an upgrade away!
Learn More About Solera Opus
The Gold Standard Nd:YAG Laser
With automatic calibration and dial-to-adjust spot size, the CoolGlide® Vantage is the industry-leading 1064 nm laser.
Learn More About CoolGlide Vantage
The CoolGlide® Excel combines the ability to treat a full range of vascular lesions with permanent hair removal on all skin types and tanned skin.
Learn More About CoolGlide Excel
The CoolGlide® CV combines excellent performance for the permanent reduction of unwanted hair with the ability to treat all skin types and tanned skin.
Learn More About CoolGlide CV
Device Overview
There is growing demand among patients and practitioners for a more aggressive treatment to address wrinkles and uneven texture while minimizing the recovery time experienced from other ablative technologies. With a 2790 nm wavelength, the Pearl laser provides a technology to meet these market demands; maximizing the ratio of cosmetic benefit to patient downtime.
Pearl
The Titan® is the first tailored infrared light source for sustained deep dermal heating. Clinicians most commonly treat the face, neck and abdomen, achieving high patient satisfaction in 1 to 3 treatment sessions. Titan treatments are comfortable and safe; made so by epidermal cooling, before, during and after treatment. Another major advantage of Titan is the low cost of ownership. Titan V
Titan XL
The first 3 in 1 Programmable Wavelength skin rejuvenation for the treatment of red and brown dyschromia and facial telangiectasia.
LimeLight
The ProWave 770™ technology allows practitioners wavelength flexibility - the ability to select the optimal wavelength distribution for hair removal in different skin type patients.
ProWave 770
The AcuTip 500™ is the first light-based technology to offer a contact tip in the ideal size to treat small vessels and lesions on the face and hands.
AcuTip 500
For permanent hair reduction, skin rejuvenation and vascular conditions, Cutera has created a long-pulse 1064 nm laser that represents several clinical firsts.
Nd:YAG Laser
©2008 Cutera, Inc. Contact Us Language: English | Japanese German French Spanish
Recent CUTR News
- Cutera to Announce First Quarter Results on May 9, 2024 • Business Wire • 04/26/2024 12:00:00 PM
- Cutera® Announces the North America Launch of xeo®+ • Business Wire • 04/11/2024 12:00:00 PM
- Cutera Announces Fourth Quarter and Full-Year 2023 Financial Results Along with 2024 Outlook • Business Wire • 03/21/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:53:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:52:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:51:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:49:28 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 03/05/2024 09:34:05 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 03/05/2024 09:31:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/05/2024 09:29:37 PM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 03/05/2024 09:24:54 PM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 03/05/2024 09:21:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 09:18:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 09:13:01 PM
- Cutera to Announce Fourth Quarter and Full-Year 2023 Results on March 21, 2024 • Business Wire • 03/01/2024 01:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 11:01:35 AM
- Cutera Announces the International Limited Commercial Release of AviClear® at IMCAS World Congress 2024 • Business Wire • 02/08/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 09:20:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 01:05:32 PM
- Cutera, Inc. Announces Preliminary Unaudited Financial Results for Full-Year 2023 • Business Wire • 01/09/2024 01:00:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 12/29/2023 11:02:19 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 09:32:37 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 11/27/2023 09:01:24 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 11:43:37 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 11/17/2023 09:01:53 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM